In kids with immune-mediated inflammatory diseases, multitargeted therapy may benefit some, with over half achieving ...

Earlier deployment of ARPIs, PARP inhibitors, and PSMA radioligand therapy yields deeper initial control but creates heavily pretreated mCRPC with complex resistance and cumulative toxicity ...

Targeted therapies are cancer medications that work more selectively than standard chemotherapy medications. They do this by targeting specific molecules or genetic changes in cancer cells in order to ...

Targeted therapy is reaching more patients than ever, but access still depends on factors like cost, insurance coverage, geography, and cancer type. These treatments offer precision and strong ...

A TOPOGRAPH-based hierarchy stratifies biomarker–drug pairs from regulatory/positive trial evidence (tiers 1–3A) to repurposing across histotypes (3B), preclinical/early data (4), and suspected ...

A new clinical trial led by the Alliance for Clinical Trials in Oncology will investigate if a combination of drug therapies after radiation therapy improves outcomes for people with newly-diagnosed, ...

Since 1921, when the first therapeutic peptide, insulin, was synthesized, many peptide-related accomplishments have reverberated throughout the industry, with more than 80 peptide drugs being approved ...

Only 35% of advanced cancer patients received comprehensive genomic profiling testing. Tested patients were more likely to receive targeted therapies. Testing rates increased slightly over time and ...

IgA nephropathy (IgAN), or Berger’s disease, is a kidney condition that occurs when abnormal immunoglobulin A (IgA) antibodies trigger inflammation in the kidneys. Until recently, treatment for IgAN ...